Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-06
DOI
10.1038/s41584-021-00726-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
- (2021) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
- (2021) Philip G. Conaghan et al. DRUG SAFETY
- Bite of the wolf: innate immune responses propagate autoimmunity in lupus
- (2021) Sarthak Gupta et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
- (2021) Yusuke Miyazaki et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
- (2021) Paqui G Traves et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- (2021) Atul Deodhar et al. ANNALS OF THE RHEUMATIC DISEASES
- Alopecia Areata
- (2021) Caiwei Zheng et al. DERMATOLOGIC CLINICS
- JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials
- (2021) Stephanie Keeling et al. Expert Review of Clinical Immunology
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials
- (2021) Yoshiya Tanaka et al. Modern Rheumatology
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
- (2021) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
- (2021) Yoshiya Tanaka Journal of Clinical Medicine
- Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
- (2021) Yoshiya Tanaka et al. Rheumatology and Therapy
- POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
- (2021) A. Armstrong et al. ANNALS OF THE RHEUMATIC DISEASES
- Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
- (2021) Silvio Danese et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- The role of antirheumatics in patients with COVID-19
- (2021) Christoffer B Nissen et al. Lancet Rheumatology
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- State‐of‐the‐art treatment of systemic lupus erythematosus
- (2020) Yoshiya Tanaka International Journal of Rheumatic Diseases
- New and Emerging Therapies for Alopecia Areata
- (2020) Aunna Pourang et al. DRUGS
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
- (2020) Justin Stebbing et al. EMBO Molecular Medicine
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
- (2020) Azucena Salas et al. Nature Reviews Gastroenterology & Hepatology
- Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
- (2020) Stanley Cohen et al. Arthritis & Rheumatology
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2020) Michael F. Robinson et al. Arthritis & Rheumatology
- Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2020) Faping Wang et al. MAYO CLINIC PROCEEDINGS
- Update οn the diagnosis and management of systemic lupus erythematosus
- (2020) Antonis Fanouriakis et al. ANNALS OF THE RHEUMATIC DISEASES
- Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability
- (2020) Manabu Narisawa et al. BONE
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
- (2020) Andrea Rubbert-Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
- (2020) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Why remission is not enough: underlying disease mechanisms in RA that prevent cure
- (2020) Georg Schett et al. Nature Reviews Rheumatology
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study
- (2020) Yoshiya Tanaka et al. RHEUMATOLOGY
- JAK1 inhibition and inflammatory bowel disease
- (2020) Clare Harris et al. RHEUMATOLOGY
- Pathophysiology, assessment and treatment of psoriatic dactylitis
- (2019) Dennis McGonagle et al. Nature Reviews Rheumatology
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
- (2019) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
- (2019) Silvio Danese et al. GUT
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis
- (2019) Ana B. Pavel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- New therapies for systemic lupus erythematosus — past imperfect, future tense
- (2019) Grainne Murphy et al. Nature Reviews Rheumatology
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰
- (2019) Yoshiya Tanaka et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
- (2019) Arlene Bravo et al. Nature Reviews Rheumatology
- The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis
- (2019) Joachim Sieper et al. Nature Reviews Rheumatology
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
- (2019) Désirée van der Heijde et al. LANCET
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- (2019) Eric F. Morand et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheSTAT4SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE
- (2018) Niklas Hagberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical management of psoriatic arthritis
- (2018) Filip Van den Bosch et al. LANCET
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- Rheumatoid arthritis
- (2018) Josef S. Smolen et al. Nature Reviews Disease Primers
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Pathogenetic insights from the treatment of rheumatoid arthritis
- (2017) Iain B McInnes et al. LANCET
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Current and emerging therapeutic targets for IBD
- (2017) Markus F. Neurath Nature Reviews Gastroenterology & Hepatology
- Enthesitis: from pathophysiology to treatment
- (2017) Georg Schett et al. Nature Reviews Rheumatology
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Psoriatic Arthritis
- (2017) Christopher T. Ritchlin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Rheumatoid arthritis
- (2016) Josef S Smolen et al. LANCET
- Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE
- (2016) Thomas Dörner et al. Nature Reviews Rheumatology
- Understanding inflammatory bowel disease via immunogenetics
- (2015) Katrina M. de Lange et al. JOURNAL OF AUTOIMMUNITY
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
- (2013) Satoshi Kubo et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
- (2012) Y Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Taming lupus—a new understanding of pathogenesis is leading to clinical advances
- (2012) Zheng Liu et al. NATURE MEDICINE
- The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
- (2011) Keisuke Maeshima et al. ARTHRITIS AND RHEUMATISM
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started